Get in touch
contact@laverocktx.com
OUR SCIENCE
Therapeutics
Ex vivo GEiGS®-enabled cell therapies
Laverock is developing GEiGS engineered cell therapies in two core areas – regenerative medicine and oncology. Regenerative medicine applications are focused on T1D, where we are generating engineered hypoimmune pancreatic islet cells, targeting product profiles with improved safety, efficacy and accessability.
Oncology programs are seeking to address the considerable challenge in development of cell therapies that can resist and remain active in the immunosuppressive tumour microenvironment, associated with solid-tumours. In this context GEiGS can programmably enable cellular phenotypes with improved efficacy without negative safety implications.
Our Pipeline
GEiGS engineered, iPSC-derived pancreatic islet cells with programmable hypoimmune status.
Oncology: GEiGS® enabled T-cells for solid tumoursGEiGS engineered, autologous T-cells with enhanced functionality for solid tumour indications.
GEiGS® enabled macrophages for solid tumoursGEiGS engineered, iPSC-derived macrophages with enhanced functionality for solid tumour indications.
In-vivo therapeutics
GEiGS core stable, tunable and programmable gene silencing is widely applicable to addressing a range of disease areas. We are generating proof of concept data and actively seeking partners to exemplify its differentiation from existing in-vivo RNAi modalities, and ability for a ‘once-and-done’ RNAi approach.
Speak to one of our team
To find out more about our technology and discuss partnering opportunities, please get in touch.
